Latest news with #SERGEIGAPON
Scotsman
28-05-2025
- Sport
- Scotsman
What time is Conference League final on TV? Full details
TNT Sports has confirmed the Conference League start time on TV ⚽ Sign up to our daily newsletter Sign up Thank you for signing up! Did you know with a Digital Subscription to Edinburgh News, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... Chelsea are gunning for European glory. The Blues will take on Real Betis in the Conference League final. But what time does coverage begin on TV? It is almost time for the final of the Conference League and anticipation is truly building. Chelsea are looking to cap their season with a European trophy - after securing a spot in next season's Champions League. Standing between the Blues and another night of glory in Europe is La Liga side Real Betis. The sides are set to meet at the Wrocław Stadium in Poland tonight (May 28). Advertisement Hide Ad Advertisement Hide Ad For fans - and neutrals - wanting to watch the action back at home, you will want to make sure you know where exactly to find the match on your TV. Here's all you need to know: What time is the Conference League on TV today? Chelsea head coach Enzo Maresca | SERGEI GAPON/AFP via Getty Images The action in Poland will kick-off at 8pm tonight, it has been confirmed. However the television coverage is set to begin with plenty of time before that. TNT Sports and Discovery+ will be broadcasting live from the Wroclaw Stadium from 6.30pm. It means there will be plenty of time for build-up to the match. Advertisement Hide Ad Advertisement Hide Ad Which channel is the Conference League final on? Since the 2015-16 season TNT Sports (formerly BT Sports) has been the home of European football in the UK. It includes the newest competition - the Conference League - and the broadcaster will be showing all the action from the Wroclaw Stadium tonight. It will be live on TNT Sports 1 and TNT Sports Ultimate - as well as on Discovery+ for free. Who are the pundits and commentators? FourFourTwo reports that Emma Dodds will be on presenting duty for the match this evening. She will be joined by pundits Michail Antonio, Joe Cole and Steve Sidwell. The commentary team will be Adam Summerton and Lucy Ward - with Becky Ives on reporting duties. Last week's Europa League final featured the likes of Gareth Bale and Rio Ferdinand as pundits. Advertisement Hide Ad Advertisement Hide Ad How to watch the Conference League final for free? If you are wondering exactly how you can tune into Chelsea vs Real Betis on May 28, TNT has explained everything over on its website . The steps to follow are as follows: Have access to discovery+ basic account with EE TV, Sky, Prime Video, you can login or, if you haven't already, activate your discovery+ account to enjoy all three finals for no extra cost. Prime Video customers with a discovery+ Basic subscription will also be able to watch all three finals on the Prime Video app. Are new to TNT Sports and discovery+. Viewers without discovery+ simply need to download the app on their mobile device, web or access via their TV, register their details online, kick back and enjoy the game for free. No subscription required. Have Virgin Media TV, all customers in the UK can watch on channel 527. Advertisement Hide Ad Advertisement Hide Ad Have you got a story you want to share with our readers? You can now send it to us online via YourWorld at . It's free to use and, once checked, your story will appear on our website and, space allowing, in our newspapers.
Yahoo
28-05-2025
- Entertainment
- Yahoo
🗞️Today's headlines: Betis aim to make history in Poland
This article was translated into English by Artificial Intelligence. You can read the original version in 🇪🇸 here. The green and white team is seeking to win the Conference League against Chelsea, in what will be the most important match in the club's history. Not every day is a European final played, nothing like the first one, and Betis wants to write its name in history against Chelsea. Today is the day of the final in Poland and the press is echoing it.📸 SERGEI GAPON - AFP or licensors
Yahoo
28-05-2025
- Entertainment
- Yahoo
🗞️Today's headlines: Betis aim to make history in Poland
This article was translated into English by Artificial Intelligence. You can read the original version in 🇪🇸 here. The green and white team is seeking to win the Conference League against Chelsea, in what will be the most important match in the club's history. Advertisement Not every day is a European final played, nothing like the first one, and Betis wants to write its name in history against Chelsea. Today is the day of the final in Poland and the press is echoing it. Diario MARCA Diario AS Mundo Deportivo Diario SPORT Superdeporte Estadio Deportivo Sphera Sports L'Esportiu 📸 SERGEI GAPON - AFP or licensors
Forbes
27-03-2025
- Health
- Forbes
Makary's FDA Has Options In Industry Fight Over Weight Loss Drugs
Interior view of Novo Nordisk's headquarters in Denmark. It is a leading global pharmaceutical ... More company. (Photo by SERGEI GAPON/AFP via Getty Images) Americans pay more for prescription drugs than citizens in any other country—so much more that the U.S. accounts for half of world sales revenue from pharmaceuticals, but only consumes 13 percent of the total volume of prescription drugs. Compared to other wealthy nations in the Organization for Economic Co-operation and Development, the U.S. accounts for 60 percent of pharmaceutical revenues but only 24 percent of volume, according to a recent issue brief from the U.S. Department of Health and Human Services. If the newly confirmed Commissioner of the U.S. Food and Drug Administration (FDA), Dr. Marty Makary, wants to change this lopsided deal, the fight over weight loss drugs is a good place to start. The high prices Americans pay are due to several reasons, including a lack of reasonable price controls, 'patent gaming' to restrict competition as long as possible, the tendency of drug companies to set prices as high as the market will bear and no central negotiator with the power to walk away. Case in point: glucagon-like peptide-1 (GLP-1) receptor agonists, a class of drugs that are effective at controlling type 2 diabetes, helping people lose weight loss and may prevent a wide range of chronic conditions from heart disease to dementia. Although the scientific research that led to the development of GLP-1 drugs was funded by U.S. taxpayers, Americans are charged far more for them than citizens in other wealthy countries. For example, in 2023 the list price for a month's supply of Ozempic (semaglutide) in the U.S. ($936) was more than five times higher than the list price in Japan ($169), and about ten times the list price in Sweden, the United Kingdom, Australia and France, according to the Peterson-KFF Health System Tracker. List Prices for Drugs Used For Weight Loss in the U.S. Versus Other High-Income Nations When the public learned that these drugs help people lose weight, demand quickly exceeded supply. This opened the door for FDA-licensed and state-licensed compounding pharmacies to produce lower-cost copies using the same active pharmaceutical ingredients (semaglutide or tirzepatide) as brand-name GLP-1 drugs at far lower cost. About two million Americans are currently using compounded GLP-1 medications, according to Kaiser Health News. This did not sit well with Novo Nordisk and Eli Lilly, the two multinational manufacturers of FDA-approved brand-name GLP-1 drugs. To reclaim market exclusivity as quickly as possible, they raced to boost production. Last month, the FDA announced that their brand-name GLP-1 drugs are no longer in shortage. On Mar. 10, the Agency notified compounding pharmacies that they should wind down production of medications containing semaglutide or tirzepatide, or risk enforcement action. While the FDA focus is on availability, Americans are far more worried about the cost of brand-name GLP-1 drugs. This is particularly true for patients with health insurance that don't cover them. Anticipating pushback, Novo announced earlier this week that it will directly sell Wegovy to cash-paying patients at a discounted price of $499 per month. In a dig aimed at compounders, Novo said it is launching the program to give patients access to a drug that is 'authentic' and 'FDA-approved' so they can 'avoid the significant risks that can be posed by the compounding marketplace.' Lilly already sells direct-to-consumer versions of its weight loss products at prices ranging from $349 to $699 monthly, depending on the dose. In contrast to Novo, it offers its discounted versions in vials, rather than pricy autoinjectors. Since these 'discounted' monthly prices are significantly more expensive than those charged by compounders, its unclear how many cash-paying customers will be able to afford them. Losing Access to Compunded GLP-1 Drugs Worries Many Americans Who Cannot Afford the Brand-Name ... More Products The most industry-friendly option is to allow FDA enforcement to proceed. If, however, compounding pharmacies are forced to stop production, many Americans currently using GLP-1 products will be unable to afford the brand-name drugs. That number could quickly grow. GoodRx recently reported that 4.9 million people whose health insurance covered Zepbound last year lost coverage of the drug in 2025. About 1.1 million lost coverage of Wegovy. If Congress cuts Medicaid, states that currently cover GLP-1 drugs will probably stop. None of this will sit well with low and middle-income voters. Novo and Lilly profit from GLP-1 sales in Europe, Japan and elsewhere, but they make much bigger profits selling the same products in the United States. That's because longstanding U.S. policies and practices allow them to charge American patients higher prices. The gap is so large, its unlikely that either company will voluntarily relent. Enabling lower-cost competition may be a better option. Under this scenario, compounding pharmacies will not be allowed to sell weight loss products using the same doses and dose-escalation schedules as Novo and Lilly. They could, however, keep making personalized doses of semaglutide or tirzepatide as long as a reasonable medical necessity (such as avoidance of intolerable adverse effects) is stated in the prescriber's order. This scenario would allow FDA 503B and state-licensed 503A compounders to keep producing affordable doses of semaglutide and tirzepatide in exchange for reasonable royalty payments. The catch is reaching agreement on a price that's 'reasonable.' If Lilly and Novo seek to replace their huge profit margins with equally large royalty payments, this idea won't work. If a fair deal cannot be reached, the Trump administration could invoke a seldom-used federal law (28 U.S. Code § 1498) that gives the U.S. government the power to produce or use a patented product without the permission of the patent holder in exchange for reasonable compensation. In past cases, this was typically about 10% of the manufacturer's annual sales. In the case of brand-name GLP-1 drugs, that's a consequential sum, but it would be substantially less than the amount Medicare, the Veterans Health Administration and other public and private payers shell out today. Once the rights are secured, the FDA could authorize FDA-licensed 503B and state-licensed 503A compounding pharmacies to produce personalized doses of semaglutide and tirzepatide at prices patients can afford. Alternatively, the FDA could seek to roll back the secondary patents on semaglutide Novo Nordisk secured to extend its control of U.S. sales well beyond the date its core patent expires. Currently, semagultide will go generic in most countries in 2026, but not in the U.S. until 2033. Brazilian drugmaker Hypera has already announced plans to launch a generic version when the drug's patent protection expires in Brazil in Mar. 2026. Eli Lilly's core patent on tirzepatide does not expire until 2036. Remarkably, the FDA is preparing to shut down competition from compounders without knowing whether the outcomes of patients taking their GLP-1 drugs are worse, the same or better than those taking a brand-name weight-loss drug. If compounded GLP-1 drugs are as 'risky' as Novo and Lilly want us to believe, a well-designed study should prove it. But if they work as well as the brand name drugs, and the flexible dosing they allow results in fewer side effects and higher sustainment, they may be an excellent alternative for many patients. In addition to pausing enforcement to collect objective data, Dr. Makary could direct the FDA to allow, if not encourage, independent testing of compounded drugs to assure their quality. Since reputable compounders already test their products before sale, they should welcome this policy. Independent testing would allow purchasers of GLP-1 drugs to choose their supplier based on quality as well as price. How Makary's FDA resolves the fight over weight loss drugs could affect the health and well-being of millions of Americans and tens of billions in annual health care costs. It could also influence how brand-name drug prices are set in the U.S. for years to come. If President Trump and RFK Jr. give their new FDA Commissioner the latitude he deserves, it will be Dr. Makary's call.
